From: A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
No. of patients (n = 725) | |
---|---|
Median age (range), years | 56 (22–86) |
Male gender | 473 (65%) |
Prior therapy | |
Surgery | 364 (50%) |
Adjuvant chemotherapy ± radiotherapy | 145 (20%) |
First-line chemotherapy* | |
FP (± leucovorin) or XP | 402 (56%) |
ECF or ECX | 29 (4%) |
Taxane (paclitaxel or docetaxel) + cisplatin | 252 (35%) |
Irinotecan- or oxaliplatin-based | 42 (6%) |
Response to first-line chemotherapy | |
Responder | 143 (20%) |
Non-responder or unknown | 582 (80%) |
Treatment-free interval, months | |
Median (range) | 2 (1–26) |
ECOG† performance status | |
0–1 | 586 (81%) |
2 or more | 139 (19%) |
Involved site(s) | |
Two or more involved sites | 283 (39%) |
Ascites | 193 |
Liver metastasis | 139 |
Bone marrow involvement (n = 69) | 41 |
Baseline laboratory parameters, median | |
Hemoglobin, g/l | 9.8 |
Albumin, g/dl | 3.4 |
Alkaline phosphatase, U/l | 86 |
Bilirubin, mg/dl | 0.5 |
Calcium, mg/dl | 8.9 |